P046: Starch consumption is associated with serologic responses in patients with ulcerative colitis and an ileo-anal pouchECCO '17 Barcelona
2017
P047: Therapeutic dosing of filgotinib (GS-6034, GLPG0634) is efficacious in the mouse DSS model of colitisECCO '17 Barcelona
2017
P048: Decreased expression of aquaporins in colonic biopsies from collagenous colitis patients. A novel diarrhoeal pathomechanism?ECCO '17 Barcelona
2017
P049: Lewis score: a useful tool for the diagnosis but not for the definition of prognosis in suspected Crohn's diseaseECCO '17 Barcelona
2017
P050: Centrally-determined standardization of flow cytometry methods reduces inter-laboratory variation in a prospective multicenter studyECCO '17 Barcelona
2017
P051: Use of digital technology to boost patient recruitment in inflammatory bowel disease clinical trialsECCO '17 Barcelona
2017
P053: Circulating non-classical monocytes are reduced in patients with active IBD but increase after vedolizumab: a role for α4β7 in myeloid cell recruitment to the inflamed intestineECCO '17 Barcelona
2017
P054: Metformin protects against intestinal barrier disruption via AMPKα1-dependent inhibition of JNK signaling pathwayECCO '17 Barcelona
2017
P055: Mitochondrial DNA is a damage-associated molecular pattern released during active IBD promoting TLR9-mediated inflammationECCO '17 Barcelona
2017
P056: Gut microbiota characterisation in South Asian IBD patients resident in the UKECCO '17 Barcelona
2017
P057: IL-6 induces NLRP3 inflammasome activation through JAK/STAT3-dependent NOX2 induction in colon epithelial cellsECCO '17 Barcelona
2017
P058: Comparison of Calprotectin levels in stool and rectal mucus in subjects with suspected or confirmed inflammatory bowel diseaseECCO '17 Barcelona
2017
P059: Mucosal inflammation promotes activation of circulating Vδ2+ T-cells in Crohn's diseaseECCO '17 Barcelona
2017
P060: Role of innate lymphoid cells in the chronic colitis under anti-il-17a therapyECCO '17 Barcelona
2017
P061: Epigenetic alterations at diagnosis predict susceptibility, prognosis and treatment escalation in inflammatory bowel disease – IBD CharacterECCO '17 Barcelona
2017
P062: The narrow spectrum kinase inhibitor TOP1288 demonstrates potent anti-inflammatory effects in a T cell adoptive transfer colitis model through a topical mode of actionECCO '17 Barcelona
2017
P063: HDAC as versatile regulators of the intestinal epithelial barrier in inflammatory bowel diseaseECCO '17 Barcelona
2017
P064: EBI2 and oxysterols in the development of intestinal lymphoid structures and colitisECCO '17 Barcelona
2017
P065: Effects of gut bacteria on the intestinal immune cell composition and barrier functionECCO '17 Barcelona
2017